PCSK9 and familial hyperaldosteronism: The backbone of pharmacotherapy is statins, which even at high doses only deliver moderate reductions (10-25%) in LDL-C in most FH patients and are often coupled with ezetimibe (an additional 10-15% reduction) [5,9]. Other cholesterol-lowering medications, such as PCSK9 inhibitors, bile acid sequestrants, niacin, and fibrates, are also used.